Gilmore O'Neill - 02 Mar 2023 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role: CEO, Director
Signature: /s/ Damien Grierson, Attorney-in-Fact
Issuer symbol: EDIT
Transactions as of: 02 Mar 2023
Transactions value $: $0
Form type: 4
Filing time: 06 Mar 2023, 15:30:11 UTC
Previous filing: 27 Jun 2022
Next filing: 07 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EDIT	Common Stock	Award	$0	+50K	+57.7%	$0.00	137K	02 Mar 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EDIT	Stock Option (right to buy)	Award	$0	+150K		$0.00	150K	02 Mar 2023	Common Stock	150K	$8.72	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027.
F2	This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.